This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998–1012. doi: 10.1056/NEJMra041245TsaoHAtkinsMBSoberAJ. Management of cutaneous melanoma. N Engl J Med2004;351:998–1012. doi:10.1056/NEJMra041245Open DOISearch in Google Scholar
Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res 2017;27:189–99. doi: 10.1097/CMR.0000000000000345HintzscheJDGordenNTAmatoCMKimJWuenschKERobinsonSEApplegateAJCoutsKLMedinaTMWellsKRWisellJAMcCarterMDBoxNFShellmanYGGonzalezRCLewisKDTentlerJJTanACRobinsonWA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res2017;27:189–99. doi:10.1097/CMR.0000000000000345Open DOISearch in Google Scholar
Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E, Shenoy A, Ayasun R, Knafo N, Xu S, Anafi L, Yanovich-Arad G, Barnabas GD, Ashkenazi S, Besser MJ, Schachter J, Bosenberg M, Shadel GS, Barshack I, Kaech SM, Markel G, Geiger T. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 2019;179:236–50.e18. doi: 10.1016/j.cell.2019.08.012HarelMOrtenbergRVaranasiSKMangalharaKCMardamshinaMMarkovitsEBaruchENTrippleVArama-ChayothMGreenbergEShenoyAAyasunRKnafoNXuSAnafiLYanovich-AradGBarnabasGDAshkenaziSBesserMJSchachterJBosenbergMShadelGSBarshackIKaechSMMarkelGGeigerT. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell2019;179:236–50.e18. doi:10.1016/j.cell.2019.08.012Open DOISearch in Google Scholar
Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, Hamerschlak N. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol 2018;11(1):65. doi: 10.1186/s13045-018-0608-2PeriniGFRibeiroGNPinto NetoJVCamposLTHamerschlakN. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol2018;11(1):65. doi:10.1186/s13045-018-0608-2Open DOISearch in Google Scholar
Murphy E, Imahashi K, Steenbergen C. Bcl-2 regulation of mitochondrial energetics. Trends Cardiovas Med 2005;15:283–90. doi: 10.1016/j.tcm.2005.09.002MurphyEImahashiKSteenbergenC. Bcl-2 regulation of mitochondrial energetics. Trends Cardiovas Med2005;15:283–90. doi:10.1016/j.tcm.2005.09.002Open DOISearch in Google Scholar
Nys K, Agostinis P. Bcl-2 family members: essential players in skin cancer. Cancer Lett 2012;320:1–13. doi: 10.1016/j.canlet.2012.01.031NysKAgostinisP. Bcl-2 family members: essential players in skin cancer. Cancer Lett2012;320:1–13. doi:10.1016/j.canlet.2012.01.031Open DOISearch in Google Scholar
Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011;18:571–80. doi: 10.1038/cdd.2010.191KangRZehHJLotzeMTTangD. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ2011;18:571–80. doi:10.1038/cdd.2010.191Open DOISearch in Google Scholar
Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, Van Moer K, Kreis S, Guerin C, Buart S, Robert C, Borg C, Vielh P, Chouaib S, Berchem G, Janji B. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A 2017;114(44):E9271–9. doi: 10.1073/pnas.1703921114MgrditchianTArakelianTPaggettiJNomanMZViryEMoussayEVan MoerKKreisSGuerinCBuartSRobertCBorgCVielhPChouaibSBerchemGJanjiB. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A2017;114(44):E9271–9. doi:10.1073/pnas.1703921114Open DOISearch in Google Scholar
Pojskić L, Haverić S, Lojo-Kadrić N, Hadzić M, Haverić A, Galić Z, Galić B, Vullo D, Supuran CT, Milos M. Effects of dipotassium-trio xohydroxytetrafluorotriborate, K2[B3O3F4OH], on cell viability and gene expression of common human cancer drug targets in a melanoma cell line. J Enzyme Inhib Med Chem 2016;31:999–1004. doi: 10.3109/14756366.2015.1078329PojskićLHaverićSLojo-KadrićNHadzićMHaverićAGalićZGalićBVulloDSupuranCTMilosM. Effects of dipotassium-trio xohydroxytetrafluorotriborate, K2[B3O3F4OH], on cell viability and gene expression of common human cancer drug targets in a melanoma cell line. J Enzyme Inhib Med Chem2016;31:999–1004. doi:10.3109/14756366.2015.1078329Open DOISearch in Google Scholar
Galić B. Boroxine composition for removal of skin changes. Patent US 8, 278, 289 B22 October 2, 2012 [displayed 28 February 2023]. Available at https://patentimages.storage.googleapis.com/9b/b7/82/939ed401b099e9/US8278289.pdfGalićB. Boroxine composition for removal of skin changes. Patent US 8, 278, 289B22 October 2, 2012 [displayed 28 February 2023]. Available at https://patentimages.storage.googleapis.com/9b/b7/82/939ed401b099e9/US8278289.pdfSearch in Google Scholar
Ivanković S, Stojković R, Galić Z, Galić B, Ostojić J, Marasović M, Miloš M. In vitro and in vivo antitumor activity of the halogenated boroxine dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]). J Enzyme Inhib Med Chem 2015;30:354–9. doi: 10.3109/14756366.2014.926344IvankovićSStojkovićRGalićZGalićBOstojićJMarasovićMMilošM. In vitro and in vivo antitumor activity of the halogenated boroxine dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]). J Enzyme Inhib Med Chem2015;30:354–9. doi:10.3109/14756366.2014.926344Open DOISearch in Google Scholar
Hadžić M, Pojskić L, Lojo-Kadrić N, Haverić A, Ramić J, Galić B, Haverić S. Novel boron-containing compound, halogenated boroxine, induces selective cytotoxicity through apoptosis triggering in UT-7 leukemia. J Biochem Mol Toxicol 2022;36(5):e23005. doi: 10.1002/jbt.23005HadžićMPojskićLLojo-KadrićNHaverićARamićJGalićBHaverićS. Novel boron-containing compound, halogenated boroxine, induces selective cytotoxicity through apoptosis triggering in UT-7 leukemia. J Biochem Mol Toxicol2022;36(5):e23005. doi:10.1002/jbt.23005Open DOISearch in Google Scholar
Haverić S, Haverić A, Bajrović K, Galić B, Maksimović M. Effects of dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]) on genetic material and inhibition of cell division in human cell cultures. Drug Chem Toxicol 2011;34:250–4. doi: 10.3109/01480545.2010.507207HaverićSHaverićABajrovićKGalićBMaksimovićM. Effects of dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]) on genetic material and inhibition of cell division in human cell cultures. Drug Chem Toxicol2011;34:250–4. doi:10.3109/01480545.2010.507207Open DOISearch in Google Scholar
Islamović S, Galić B, Miloš M. A study of the inhibition of catalase by dipotassium trioxohydroxytetrafluorotriborate K2[B3O3F4OH]. J Enzyme Inhib Med Chem 2014;29:744–8. doi: 10.3109/14756366.2013.848203IslamovićSGalićBMilošM. A study of the inhibition of catalase by dipotassium trioxohydroxytetrafluorotriborate K2[B3O3F4OH]. J Enzyme Inhib Med Chem2014;29:744–8. doi:10.3109/14756366.2013.848203Open DOISearch in Google Scholar
Ostojić J, Herenda S, Galijašević S, Galić B, Miloš M. Inhibition of horseradish peroxidase activity by boroxine derivative, dipotassium-tr ioxohydroxytetrafluorotriborate K2[B3O3F4OH]. J Chem 2017;2017:8134350. doi: 10.1155/2017/8134350OstojićJHerendaSGalijaševićSGalićBMilošM. Inhibition of horseradish peroxidase activity by boroxine derivative, dipotassium-tr ioxohydroxytetrafluorotriborate K2[B3O3F4OH]. J Chem2017;2017:8134350. doi:10.1155/2017/8134350Open DOISearch in Google Scholar
Herenda S, Ostojić J, Hasković E, Hasković D, Miloš M, Galić B. Electrochemical investigation of the influence of K2[B3O3F4OH] on the activity of immobilized superoxide dismutase. Int J Electrochem Sci 2018;13:3279–87. doi: 10.20964/2018.04.35HerendaSOstojićJHaskovićEHaskovićDMilošMGalićB. Electrochemical investigation of the influence of K2[B3O3F4OH] on the activity of immobilized superoxide dismutase. Int J Electrochem Sci2018;13:3279–87. doi:10.20964/2018.04.35Open DOISearch in Google Scholar
Vullo D, Miloš M, Galić B, Scozzafava A, Supuran CT. Dipotassium trioxohydroxytetrafluorotriborate K2[B3O3F4OH], is a potent inhibitor of human carbonic anhydrases. J Enzyme Inhib Med Chem 2015;30:341–4. doi: 10.3109/14756366.2014.918610VulloDMilošMGalićBScozzafavaASupuranCT. Dipotassium trioxohydroxytetrafluorotriborate K2[B3O3F4OH], is a potent inhibitor of human carbonic anhydrases. J Enzyme Inhib Med Chem2015;30:341–4. doi:10.3109/14756366.2014.918610Open DOISearch in Google Scholar
Ivanković S, Stojković R, Maksimović M, Galić B, Miloš M. Impact of calcium ion on cytotoxic effect of the boroxine derivative, K2[B3O3F4OH]. J Enzyme Inhib Med Chem 2016;31(Suppl 3):70–4. doi: 10.1080/14756366.2016.1204611IvankovićSStojkovićRMaksimovićMGalićBMilošM. Impact of calcium ion on cytotoxic effect of the boroxine derivative, K2[B3O3F4OH]. J Enzyme Inhib Med Chem2016;31(Suppl 3):70–4. doi:10.1080/14756366.2016.1204611Open DOISearch in Google Scholar
Hadzic M, Sun Y, Tomic N, Tsirvouli E, Kuiper M, Pojskic L. Halogenated boroxine increases propensity to apoptosis in leukemia (UT-7) but not non-tumor cells in vitro. FEBS Open Bio 2023;13:143–53. doi: 10.1002/2211-5463.13522HadzicMSunYTomicNTsirvouliEKuiperMPojskicL. Halogenated boroxine increases propensity to apoptosis in leukemia (UT-7) but not non-tumor cells in vitro. FEBS Open Bio2023;13:143–53. doi:10.1002/2211-5463.13522Open DOISearch in Google Scholar
Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995;55:2528–32. PMID: 7780963EastyDJGuthrieBAMaungKFarrCJLindbergRATosoRJHerlynMBennettDC. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res1995;55:2528–32. PMID: 7780963Search in Google Scholar
Panda SK, Ravindran B. Isolation of human PBMCs. Bio-protocol 2013;3(3):e323. doi: 10.21769/BioProtoc.323PandaSKRavindranB. Isolation of human PBMCs. Bio-protocol2013;3(3):e323. doi:10.21769/BioProtoc.323Open DOISearch in Google Scholar
Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors 2012;12:12347–60. doi: 10.3390/s120912347RampersadSN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors2012;12:12347–60. doi:10.3390/s120912347Open DOISearch in Google Scholar
Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the alamarBlue assay. Cold Spring Harb Protoc 2018;6:095489. doi: 10.1101/pdb.prot095489KumarPNagarajanAUchilPD. Analysis of cell viability by the alamarBlue assay. Cold Spring Harb Protoc2018;6:095489. doi:10.1101/pdb.prot095489Open DOISearch in Google Scholar
AlamarBlue® Assay, U.S. Patent No. 5,501,959 [displayed 22 February 2023]. Available at https://tools.thermofisher.com/content/sfs/manuals/PI-DAL1025-1100_TI%20alamarBlue%20Rev%201.1.pdfAlamarBlue® Assay, U.S. Patent No. 5,501,959 [displayed 22 February 2023]. Available at https://tools.thermofisher.com/content/sfs/manuals/PI-DAL1025-1100_TI%20alamarBlue%20Rev%201.1.pdfSearch in Google Scholar
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30(9):e36. doi: 10.1093/nar/30.9.e36PfafflMWHorganGWDempfleL. Relative expression software tool (REST) for group wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res2002;30(9):e36. doi:10.1093/nar/30.9.e36Open DOISearch in Google Scholar
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402–8. doi: 10.1006/meth.2001.1262LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods2001;25:402–8. doi:10.1006/meth.2001.1262Open DOISearch in Google Scholar
Zhang XD, Qi L, Wu JC, Qin ZH. DRAM1 regulates autophagy flux through lysosomes. PLoS One 2013;8(5):e63245. doi: 10.1371/journal.pone.0063245ZhangXDQiLWuJCQinZH. DRAM1 regulates autophagy flux through lysosomes. PLoS One2013;8(5):e63245. doi:10.1371/journal.pone.0063245Open DOISearch in Google Scholar
Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Campanella M, Grose R, Jones C, Salomoni P. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013;32:699–712. doi: 10.1038/onc.2012.111GalavottiSBartesaghiSFaccendaDShaked-RabiMSanzoneSMcEvoyADinsdaleDCondorelliFBrandnerSCampanellaMGroseRJonesCSalomoniP. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene2013;32:699–712. doi:10.1038/onc.2012.111Open DOISearch in Google Scholar
Vats S, Manjithaya R. A reversible autophagy inhibitor blocks autophagosome-lysosome fusion by preventing Stx17 loading onto autophagosomes. Mol Biol Cell 2019;30:2283–95. doi: 10.1091/mbc.E18-08-0482VatsSManjithayaR. A reversible autophagy inhibitor blocks autophagosome-lysosome fusion by preventing Stx17 loading onto autophagosomes. Mol Biol Cell2019;30:2283–95. doi:10.1091/mbc.E18-08-0482Open DOISearch in Google Scholar
Kumar AV, Mills J, Lapierre LR. Selective autophagy receptor p62/SQSTM1, a pivotal player in stress and aging. Front Cell Dev Biol 2022;10:793328. doi: 10.3389/fcell.2022.793328KumarAVMillsJLapierreLR. Selective autophagy receptor p62/SQSTM1, a pivotal player in stress and aging. Front Cell Dev Biol2022;10:793328. doi:10.3389/fcell.2022.793328Open DOISearch in Google Scholar